

Ref no: 100250219
From: Commercial
Date: 25/02/19
Subject: Biosimilar biologic therapies.

REQUEST & RESPONSE

Pharmacy Response: Data 1st April 2018- 18th March 2019

1. Does your trust use the following biosimilar biologic therapies, and if possible how many patients are currently being treated ?

Adalimumab [Hyrimoz]	No/Yes [if Yes number	NO	
Adalimumab [Amgevita]	No/Yes [if Yes number	YES	33
Adalimumab [Imraldi]	No/Yes [if Yes number	NO	
Adalimumab [Hulio]	No/Yes [if Yes number	NO	
Etanercept [Benepali]	No/Yes [if Yes number	YES	119
Etanercept [Erelzi]	No/Yes [if Yes number	NO	
Infliximab [Inflectra]	No/Yes [if Yes number	NO	
Infliximab [Remsima]	No/Yes [if Yes number	YES	227
Infliximab [Flixabi]	No/Yes [if Yes number	NO	

2. Within your rheumatology department;

a. how many patients in the year 2018 were treated with a biologic or JAK2-

324

b. how many patients in the year 2018 were treated with a DMARD [for example azathioprine, ciclosporin, methotrexate, hydroxychloroquine, leflunomide, sulfasalazine or minocycline]

923

3. Within your dermatology department;

a. how many patients in the year 2018 were treated with a biologic or JAK2

49

b. how many patients in the year 2018 were treated with a DMARD [for example azathioprine, ciclosporin, methotrexate, hydroxychloroquine, leflunomide, sulfasalazine or minocycline]

453

4. Within your gastroenterology department:

a. how many patients in the year 2018 were treated with a biologic or JAK2

213

b. how many patients in the year 2018 were treated with a DMARD [for example azathioprine, ciclosporin, methotrexate, hydroxychloroquine, leflunomide, sulfasalazine or minocycline]

206

5. Does your trust record the DAS score electronically on the patient records?,
If so how many are DAS 5+ No/Yes [if Yes number]

The Trust does not routinely record (either on paper or electronically) a DAS (disease activity score) for the IBD patients attending clinic or endoscopy.